Capromorelin – (193273-66-4)

Capromorelin is a molecule used for the management of weight loss in cats and dogs. It is a ghrelin receptor agonist known to increase appetite and weight gain.

Capromorelin was developed by Pfizer and approved for veterinary use in the United States in May 2016. It is the second drug approved for the management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease.

Capromorelin functions to stimulate the secretion of growth hormone and as a ghrelin mimetic, which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) and growth hormone levels.

As of 2017, capromorelin studies in humans have been discontinued. Capromorelin is indicated for the management of weight loss in cats and dogs.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Capromorelin
https://pubchem.ncbi.nlm.nih.gov/compound/216208
https://www.medchemexpress.com/capromorelin.html
https://www.medkoo.com/products/10545
https://www.sciencedirect.com/topics/medicine-and-dentistry/capromorelin